GlobeNewswire Inc | Jul 7, 2021 08:00AM EDT

July 07, 2021

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present in a virtual format at the Ladenburg Thalmann 2021 Healthcare Conference on Wednesday, July 14, 2021 at 9:30 a.m. ET.

A live webcast of the virtual presentation can be accessed through the Events & Presentations section of the Companys website atinvestors.ovidrx.com. An archived replay of the webcast will be available on the Companys website following the live presentation.

About Ovid Therapeutics

Ovid Therapeutics Inc.is aNew York-based biopharmaceutical company using its BoldMedicine approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid couples deep CNS experience with emerging advances in genetics and the pathways of the brain to build a leading, next-generation neuroscience pipeline. Ovids current pipeline programs include: OV329, a small molecule GABA aminotransferase inhibitor for seizures associated withTuberous Sclerosis Complexand Infantile Spasms; OV882, a short hairpin RNA therapy approach for Angelman syndrome; OV815, a genetic therapy approach for KIF1A associated neurological disorder; and other non-disclosed research targets. Additionally, Ovid maintains a significant financial interest in a program directed to the advancement of soticlestat, for which Takeda is responsible for the global development and commercialization, if soticlestat is successfully developed and commercialized. For more information onOvid, please visitwww.ovidrx.com.

Contacts

Investors and Media:Ovid Therapeutics Inc.Investor Relations & Public Relationsirpr@ovidrx.com

OR

Investors:Argot PartnersDawn Schottlandt212-600-1902ovid@argotpartners.com

Media:Dan Budwick1ABdan@1abmedia.com